These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 15525301)

  • 41. The natural history of CADASIL: a pooled analysis of previously published cases.
    Desmond DW; Moroney JT; Lynch T; Chan S; Chin SS; Mohr JP
    Stroke; 1999 Jun; 30(6):1230-3. PubMed ID: 10356105
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cognitive impairment and cerebral hypoperfusion in a CADASIL patient improved during administration of lomerizine.
    Mizuno T; Kondo M; Ishigami N; Tamura A; Itsukage M; Koizumi H; Isayama R; Hosomi A; Nagakane Y; Tokuda T; Sugimoto E; Ushijima Y; Nakagawa M
    Clin Neuropharmacol; 2009; 32(2):113-6. PubMed ID: 19512965
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Cross-Sectional Analysis of Migraine-Related Disability in CADASIL: A Mayo Clinic Cohort.
    Goldstein ED; Badi MK; Klaas JP; Glover P; Rozen TD; Huang JF; Lin MP; Meschia JF
    Neurologist; 2019 Nov; 24(6):161-164. PubMed ID: 31688705
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intracerebral hemorrhage in CADASIL.
    Palazzo P; Le Guyader G; Neau JP
    Rev Neurol (Paris); 2021 Apr; 177(4):422-430. PubMed ID: 33478738
    [TBL] [Abstract][Full Text] [Related]  

  • 45. General anesthesia considerations in CADASIL disease.
    Bermúdez-Triano M; Guerrero-Domínguez R; Martínez-Saniger A; Jiménez I
    Rev Esp Anestesiol Reanim (Engl Ed); 2019 Apr; 66(4):226-229. PubMed ID: 30665799
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Simultaneous subcortical infarcts as initial manifestation of CADASIL.
    Taieb G; Renard D; Castelnovo G
    Acta Neurol Belg; 2015 Sep; 115(3):385-6. PubMed ID: 25163556
    [No Abstract]   [Full Text] [Related]  

  • 47. [Clinical variability and diagnostic controversies in CADASIL].
    García-Barragán N; Fernández-Guarino M; Jiménez-Escrig A
    Rev Clin Esp; 2007 Apr; 207(4):187-9. PubMed ID: 17475182
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pathological gambling associated with CADASIL: an unusual manifestation.
    Plastino M; Messina D; Cristiano D; Lombardo G; Bosco D
    Neurol Sci; 2015 Oct; 36(10):1963-5. PubMed ID: 26142163
    [No Abstract]   [Full Text] [Related]  

  • 49. Genetically determined vascular diseases.
    Rafałowska J
    Folia Neuropathol; 1999; 37(4):210-6. PubMed ID: 10705639
    [TBL] [Abstract][Full Text] [Related]  

  • 50. COVID-19-Associated Acute Multi-infarct Encephalopathy in an Asymptomatic CADASIL Patient.
    Zhang T; Hirsh E; Zandieh S; Rodricks MB
    Neurocrit Care; 2021 Jun; 34(3):1099-1102. PubMed ID: 33025544
    [No Abstract]   [Full Text] [Related]  

  • 51. Cysteine-Altering NOTCH3 Variants Are Associated with an Increased Risk of Autoimmune Diseases.
    Rieder E; Li J; Rodriguez-Flores JL; Taimur Malik M; Abedi V; Zand R
    J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834922
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CADASIL vs. Multiple Sclerosis: Is It Misdiagnosis or Concomitant? A Case Series.
    Khan A; Abedi V; Li J; Malik MT; Esch M; Zand R
    Front Neurol; 2020; 11():860. PubMed ID: 33013620
    [No Abstract]   [Full Text] [Related]  

  • 53. Identification of a known mutation in Notch 3 in familiar CADASIL in China.
    Tan ZX; Li FF; Qu YY; Liu J; Liu GR; Zhou J; Zhu YL; Liu SL
    PLoS One; 2012; 7(5):e36590. PubMed ID: 22623959
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High lipoprotein(a) serum levels in three CADASIL families.
    Valenti R; Nannucci S; Pescini F; Bianchi S; Inzitari D; Pantoni L
    J Neurol; 2012 Feb; 259(2):379-80. PubMed ID: 21786151
    [No Abstract]   [Full Text] [Related]  

  • 55. First report of a pathogenic mutation on exon 24 of the NOTCH3 gene in a CADASIL family.
    Valenti R; Bianchi S; Pescini F; D'Eramo C; Inzitari D; Dotti MT; Pantoni L
    J Neurol; 2011 Sep; 258(9):1632-6. PubMed ID: 21409506
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnostic criteria for CADASIL in the International Classification of Headache Disorders (ICHD-II): are they appropriate?
    Sacco S; Degan D; Carolei A
    J Headache Pain; 2010 Jun; 11(3):181-6. PubMed ID: 20224942
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical and genetic features in a family with CADASIL and high lipoprotein (a) values.
    Gong M; Rueschendorf F; Marx P; Schulz H; Kraft HG; Huebner N; Koennecke HC
    J Neurol; 2010 Aug; 257(8):1240-5. PubMed ID: 20143106
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thrombophilic risk factors and unusual clinical features in three Italian CADASIL patients.
    Pantoni L; Sarti C; Pescini F; Bianchi S; Bartolini L; Nencini P; Basile AM; Lamassa M; Kalaria RN; Dotti MT; Federico A; Inzitari D
    Eur J Neurol; 2004 Nov; 11(11):782-7. PubMed ID: 15525301
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Migraine and cerebral white matter lesions: when to suspect cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).
    Gladstone JP; Dodick DW
    Neurologist; 2005 Jan; 11(1):19-29. PubMed ID: 15631641
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Familial hemiplegic migraine and autosomal dominant arteriopathy with leukoencephalopathy (CADASIL).
    Hutchinson M; O'Riordan J; Javed M; Quin E; Macerlaine D; Wilcox T; Parfrey N; Nagy TG; Tournier-Lasserve E
    Ann Neurol; 1995 Nov; 38(5):817-24. PubMed ID: 7486874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.